CEIPV对2021年新的欧洲心血管预防指南的评论

IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE
Carlos Brotons , Miguel Camafort , María del Mar Castellanos , Albert Clarà , Olga Cortés , Angel Diaz Rodriguez , Roberto Elosua , Manuel Gorostidi , Antonio M. Hernández , María Herranz , Soledad Justo , Carlos Lahoz , Pilar Niño , Vicente Pallarés-Carratalá , Juan Pedro-Botet , Antonio Pérez Pérez , Miguel Angel Royo-Bordonada , Rafael Santamaria , Ricard Tresserras , Alberto Zamora , Pedro Armario
{"title":"CEIPV对2021年新的欧洲心血管预防指南的评论","authors":"Carlos Brotons ,&nbsp;Miguel Camafort ,&nbsp;María del Mar Castellanos ,&nbsp;Albert Clarà ,&nbsp;Olga Cortés ,&nbsp;Angel Diaz Rodriguez ,&nbsp;Roberto Elosua ,&nbsp;Manuel Gorostidi ,&nbsp;Antonio M. Hernández ,&nbsp;María Herranz ,&nbsp;Soledad Justo ,&nbsp;Carlos Lahoz ,&nbsp;Pilar Niño ,&nbsp;Vicente Pallarés-Carratalá ,&nbsp;Juan Pedro-Botet ,&nbsp;Antonio Pérez Pérez ,&nbsp;Miguel Angel Royo-Bordonada ,&nbsp;Rafael Santamaria ,&nbsp;Ricard Tresserras ,&nbsp;Alberto Zamora ,&nbsp;Pedro Armario","doi":"10.1016/j.arteri.2022.03.003","DOIUrl":null,"url":null,"abstract":"<div><p>We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences.</p><p>The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (&lt;<!--> <!-->50, 50-69, ≥<!--> <!-->70 years).</p><p>Different flow charts of cardiovascular disease risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic cardiovascular disease, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021\",\"authors\":\"Carlos Brotons ,&nbsp;Miguel Camafort ,&nbsp;María del Mar Castellanos ,&nbsp;Albert Clarà ,&nbsp;Olga Cortés ,&nbsp;Angel Diaz Rodriguez ,&nbsp;Roberto Elosua ,&nbsp;Manuel Gorostidi ,&nbsp;Antonio M. Hernández ,&nbsp;María Herranz ,&nbsp;Soledad Justo ,&nbsp;Carlos Lahoz ,&nbsp;Pilar Niño ,&nbsp;Vicente Pallarés-Carratalá ,&nbsp;Juan Pedro-Botet ,&nbsp;Antonio Pérez Pérez ,&nbsp;Miguel Angel Royo-Bordonada ,&nbsp;Rafael Santamaria ,&nbsp;Ricard Tresserras ,&nbsp;Alberto Zamora ,&nbsp;Pedro Armario\",\"doi\":\"10.1016/j.arteri.2022.03.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences.</p><p>The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (&lt;<!--> <!-->50, 50-69, ≥<!--> <!-->70 years).</p><p>Different flow charts of cardiovascular disease risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic cardiovascular disease, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.</p></div>\",\"PeriodicalId\":45230,\"journal\":{\"name\":\"Clinica e Investigacion en Arteriosclerosis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica e Investigacion en Arteriosclerosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0214916822000365\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Arteriosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214916822000365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

我们提出了2021年欧洲心血管疾病预防临床实践指南的西班牙改编。目前的指南除了个人方法外,还非常强调人群水平方法对预防心血管疾病的重要性。建议对具有任何主要血管危险因素的个体进行系统的全球心血管疾病风险评估。关于糖尿病患者的低密度脂蛋白胆固醇、血压和血糖控制,目标和指标仍与先前指南中推荐的一样。然而,我们提出了一种新的、逐步的方法(步骤1和步骤2)来加强治疗,作为一种工具,帮助医生和患者以符合患者特征的方式追求这些目标。在第1步之后,必须考虑进入第2步的强化目标,这种强化将基于10年心血管疾病风险、终生心血管疾病风险和治疗获益、合并症和患者偏好。更新后的SCORE算法?SCORE2, SCORE2- op ?该指南估计40-89岁健康男性和女性10年发生致命性和非致命性心血管疾病事件(心肌梗死、中风)的风险。另一项新的重要建议是根据不同年龄组使用不同的风险分类(<50、50-69、≥70岁)。建议在表面健康的人、已确诊的动脉粥样硬化性心血管疾病患者和糖尿病患者中使用不同的心血管疾病危险和危险因素治疗流程图。根据肾小球滤过率和白蛋白/肌酐比值的水平,慢性肾病患者被认为是高危或高危患者。根据西班牙卫生部公布的新生活方式建议以及针对血脂、血压、糖尿病和慢性肾衰竭管理的建议进行了调整。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021

We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences.

The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (< 50, 50-69, ≥ 70 years).

Different flow charts of cardiovascular disease risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic cardiovascular disease, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinica e Investigacion en Arteriosclerosis
Clinica e Investigacion en Arteriosclerosis PERIPHERAL VASCULAR DISEASE-
CiteScore
3.20
自引率
6.20%
发文量
44
审稿时长
40 days
期刊介绍: La publicación idónea para acceder tanto a los últimos originales de investigación como a formación médica continuada sobre la arteriosclerosis y su etiología, epidemiología, fisiopatología, diagnóstico y tratamiento. Además, es la publicación oficial de la Sociedad Española de Arteriosclerosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信